Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lotus expands OTC business

This article was originally published in The Tan Sheet

Executive Summary

The Beijing-based pharma says it signed OTC drug purchase agreements with 11 manufacturers during its second quarter, when retail revenues grew 123 percent to $6.2 million, thanks largely to OTC direct sales to Beijing outlets. Lotus Pharmaceuticals only recently entered the OTC business with a new sales team and an under-construction distribution facility (1"The Tan Sheet" May 24, 2010, In Brief). The firm said Aug. 16 its overall net revenue climbed 19.4 percent to $12.7 million in the April-June period and 23.6 percent to $24.2 million in the half

You may also be interested in...



Lotus OTCs boost retail sales

Increased distribution to OTC drug outlets in Beijing helps Lotus Pharmaceuticals grow net retail revenue 52.2 percent to $3.3 million in the Chinese firm's fiscal 2010 first quarter. OTC drugs are a new venture for Lotus, which expects to expand the business with a recently recruited sales team and a storage and distribution facility under construction, the company said May 14. Overall net revenues, largely generated by Lotus' wholesale Rx segment, increased 26.4 percent to $14.9 million in the first quarter 2010. Net income rose 36.1 percent to $4.9 million

House Of Representatives Concerned Over Complex Generics

The Committee on Energy and Commerce of the US House of Representatives has requested a set of documents from the FDA in order to assess whether the agency is doing enough to address the challenge of approving complex generics within its existing authorities, or whether additional authority is needed.

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.

 

 

Topics

UsernamePublicRestriction

Register

PS104429

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel